A phase I study of IRISOX (irinotecan/S-1/oxaliplatin) in the second-line treatment for gemcitabine-refractory pancreatic cancer

被引：0
|
作者：
Miyata, E. [1 ]
Okuwaki, K. [1 ]
Imaizumi, H. [2 ]
Kida, M. [1 ]
Iwai, T. [1 ]
Yamauchi, H. [1 ]
Kaneko, T. [1 ]
Hasegawa, R. [1 ]
Adachi, K. [1 ]
Tadehara, M. [1 ]
Koizumi, W. [1 ]
机构：
[1] Kitasato Univ, Sch Med, Gastroenterol, Sagamihara, Kanagawa, Japan
[2] Sagamino Hosp, Japan Community Hlth Care Org, Gastroenterol, Sagamihara, Kanagawa, Japan
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
721P
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer
    Eiichiro Suzuki
    Masafumi Ikeda
    Takuji Okusaka
    Shoji Nakamori
    Shinichi Ohkawa
    Tatsuya Nagakawa
    Narikazu Boku
    Hiroaki Yanagimoto
    Tosiya Sato
    Junji Furuse
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1141 - 1146
  • [32] Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients
    Morizane, Chigusa
    Okusaka, Takuji
    Ueno, Hideki
    Kondo, Shunsuke
    Ikeda, Masafumi
    Furuse, Junji
    Shinichi, Ohkawa
    Nakachi, Kohei
    Mitsunaga, Shuichi
    Kojima, Yasushi
    Suzuki, Eiichiro
    Ueno, Makoto
    Yamaguchi, Tomohiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 957 - 964
  • [33] Phase I/II Trial of Irinotecan and S-1 Combination Chemotherapy as a Second-Line Treatment for Advanced Colorectal Cancer
    Takii, Yasumasa
    Yamazaki, Toshiyuki
    Okada, Takayuki
    Tani, Tatsuo
    Funakoshi, Kazuhiro
    Maruyama, Satoshi
    Hasegawa, Jun
    Akazawa, Kouhei
    Hatakeyama, Katsuyoshi
    CHEMOTHERAPY, 2013, 59 (05) : 338 - 343
  • [34] Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients
    Chigusa Morizane
    Takuji Okusaka
    Hideki Ueno
    Shunsuke Kondo
    Masafumi Ikeda
    Junji Furuse
    Ohkawa Shinichi
    Kohei Nakachi
    Shuichi Mitsunaga
    Yasushi Kojima
    Eiichiro Suzuki
    Makoto Ueno
    Tomohiro Yamaguchi
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 957 - 964
  • [35] Phase I study of S-1, irinotecan plus oxaliplatin combination therapy for advanced pancreatic cancer
    Shiba, S.
    Ueno, H.
    Chigusa, M.
    Sasaki, M.
    Oishi, T.
    Hosoi, H.
    Kondo, S.
    Sakamoto, Y.
    Okusaka, T.
    ANNALS OF ONCOLOGY, 2015, 26 : 66 - 66
  • [36] Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer
    Hitoshi Kusaba
    Taito Esaki
    Junji Kishimoto
    Keita Uchino
    Shuji Arita
    Hozumi Kumagai
    Kenji Mitsugi
    Koichi Akashi
    Eishi Baba
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 29 - 34
  • [37] Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer
    Kusaba, Hitoshi
    Esaki, Taito
    Kishimoto, Junji
    Uchino, Keita
    Arita, Shuji
    Kumagai, Hozumi
    Mitsugi, Kenji
    Akashi, Koichi
    Baba, Eishi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (01) : 29 - 34
  • [38] Oral chemotherapy as second-line treatment option for gemcitabine-refractory advanced pancreatic cancer with poor performance status.
    Park, Se Jun
    Lee, Myung Ah
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [39] A multicenter phase II of S-1 in gemcitabine-refractory biliary tract cancer
    Suzuki, E.
    Ikeda, M.
    Okusaka, T.
    Nakamori, S.
    Ohkawa, S.
    Nagakawa, T.
    Boku, N.
    Yamagimoto, H.
    Sugimori, K.
    Furuse, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [40] Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine
    Sasaki, Takashi
    Isayama, Hiroyuki
    Nakai, Yousuke
    Mizuno, Suguru
    Yamamoto, Keisuke
    Yagioka, Hiroshi
    Yashima, Yoko
    Kawakubo, Kazumichi
    Kogure, Hirofumi
    Togawa, Osamu
    Matsubara, Saburo
    Ito, Yukiko
    Sasahira, Naoki
    Hirano, Kenji
    Tsujino, Takeshi
    Toda, Nobuo
    Tada, Minoru
    Omata, Masao
    Koike, Kazuhiko
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) : 708 - 713
12345